Catalyst OrthoScience Inc., a private medical technology company specializing in shoulder arthroplasty—the fastest growing segment in the orthopedics market—has surpassed 10,000 total shoulder arthroplasty (TSA) procedures. The milestone coincides with the successful close of $20 million in equity and venture debt financing from RC Capital, Mutual Capital Partners, and Bridge Bank.
Catalyst OrthoScience has achieved a significant milestone, completing 10,000 Catalyst TSA procedures, underscoring its strong acceptance among surgeons and patients in shoulder arthroplasty. This achievement, combined with a $20 million financing boost, positions Catalyst for accelerated growth and innovation in the market. The new funding will support the next phase of commercial adoption, allowing the company to expand its distribution channels, invest in talent and training, launch new products, and solidify its standing as a leader in shoulder arthroplasty.
“Catalyst has made remarkable progress since its first procedure in 2016,” said Carl O’Connell, CEO of Catalyst. “We blend innovation with efficiency and predictable outcomes, addressing industry inefficiencies and high procedural costs that don’t necessarily improve patient outcomes. Our single-tray systems, proprietary instruments, streamlined surgical steps, and purpose-designed implants are particularly valuable as procedures increasingly move to ambulatory surgery centers (ASCs), where there’s a strong demand for solutions that reduce turnaround times, sterilization costs, and storage needs, while easing the surgical team’s workload.”
Carter McNabb, Managing Partner at RC Capital and Catalyst board member, noted, “Catalyst is unique in a rapidly growing sector. This funding will further the company’s mission to enhance shoulder arthroplasty for both surgeons and patients across all care settings.”
Bill Wickline, Managing Director in the Life Sciences Group at Bridge Bank, added, “Bridge Bank is excited to support Catalyst as it reaches this milestone and positions itself for future growth and advances in patient care.”
About Catalyst OrthoScience Inc.
Founded in 2014 by orthopedic surgeon Steven Goldberg, MD, in Naples, Florida, Catalyst OrthoScience aims to make shoulder replacements less invasive, with fewer complications and a more natural feel post-surgery. Catalyst is revolutionizing shoulder replacement surgery with total shoulder systems that ensure precision and accuracy while preserving bone and soft tissue. Catalyst holds a growing portfolio of patents and pending patents on its unique products, available throughout the U.S.
About RC Capital
RC Capital is a growth equity firm specializing in building high-potential healthcare companies across medical devices, healthcare services, and healthcare IT. Focused on advancing healthcare delivery, RC Capital invests in companies that enhance clinical care, patient experiences, and outcomes. With a 30-year history, RC Capital partners deeply with portfolio companies, providing strategic insights, access to healthcare thought leaders, and strong relationships with health systems.
